Announcements Trials
Browse Landscape

Status

Recruiting 14Not yet recruiting 6Completed 3Active not recruiting 3Enrolling by invitation 2Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Liver Diseases 1Hepatitis 1Fibrosis 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 8Carboplatin 7Pemetrexed 5Nivolumab 5Cyclophosphamide 5Cisplatin 5ixazomib 4durvalumab 4Specimen Handling 4Paclitaxel 4Bevacizumab 4ibrutinib 3fludarabine phosphate 3fludarabine 3Ipilimumab 3Gemcitabine 3Docetaxel 3Cetuximab 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2temsirolimus 2evolocumab 2enzalutamide 2daratumumab 2atezolizumab 2Trastuzumab 2Tomography, X-Ray Computed 2Standard of Care 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Blood Specimen Collection × 30 days × Clear all
NCT02908048 2026-05-05

Extracellular RNA Markers of Liver Disease and Cancer

Mayo Clinic

Terminated
1,865 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Fibrosis, Hepatitis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡